|Videos|January 24, 2023
CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies
In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).
Advertisement
Episodes in this series
Advertisement
Related to this article
Antibodies directed against TNFR2, a regulator in the TME that promotes tumor cell proliferation, have shown promise in T-cell lymphoma and ovarian cancer.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
Docirbrutinib generated responses in patients with relapsed/refractory CLL/SLL, MCL, and other non-Hodgkin lymphomas.
A rituximab biosimilar has been approved by the FDA.
FDA has granted RMAT and fast track designations to cema-cel as a frontline consolidation in large B-cell lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Issues CRL to 177Lu-Edotreotide for GEP-NETs
2
Early mRNA Vaccine Data Excite Possibilities of Long-Term PDAC Remissions
3
Expanding Options and Long-Term Data Reshape Frontline and Emerging CLL Treatment Strategies
4
Beyond “I Know It When I See It”: The Murky Reality of Conflict of Interest in Oncology
5